Clarity Pharmaceuticals Ltd (ASX: CU6) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clarity Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$2.24 billion
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
316.08 million
Earnings per share
-0.118
Dividend per share
N/A
Year To Date Return
297.02%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clarity Pharmaceuticals Ltd (ASX: CU6)
Latest News
Share Gainers
Why Beach Energy, BSA, Clarity, and Perpetual shares are pushing higher today
Speculative
Why this speculative ASX stock could rise ~50%
Healthcare Shares
4 ASX healthcare stocks having a cracking run on Friday
Share Gainers
These 4 ASX All Ords shares are up 302% to 693% in a year!
Healthcare Shares
Up 24% in a month! This ASX biotech share is hitting a record high on trial update
Earnings Results
3 ASX healthcare stocks surging after strong FY24 earnings
Record Highs
Records tumble! 10 popular ASX shares smashing new all-time highs today
Healthcare Shares
Broker urges investors to buy this ASX biotech stock for big returns
Healthcare Shares
If you invested $5,000 in this ASX pharmaceuticals stock a year ago, you'd have $34,711 now!
Share Gainers
3 ASX small-cap shares that soared 250% to 675% in FY24
Share Market News
Guess which 2 ASX All Ordinaries shares were the best and worst performers of FY24?
Share Gainers
5 ASX All Ords shares that rose 250% to 700% in FY24
CU6 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
CU6 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 04 Nov 2024 | $6.99 | $0.23 | 3.40% | 994,565 | $7.01 | $7.25 | $6.87 |
| 01 Nov 2024 | $6.76 | $-0.07 | -1.02% | 636,159 | $6.74 | $6.80 | $6.65 |
| 31 Oct 2024 | $6.83 | $-0.02 | -0.29% | 1,755,116 | $6.83 | $7.05 | $6.58 |
| 30 Oct 2024 | $6.85 | $-0.32 | -4.46% | 1,270,918 | $7.06 | $7.20 | $6.80 |
| 29 Oct 2024 | $7.17 | $-0.10 | -1.38% | 830,903 | $7.22 | $7.25 | $6.96 |
| 28 Oct 2024 | $7.27 | $0.11 | 1.54% | 988,560 | $7.10 | $7.28 | $7.07 |
| 25 Oct 2024 | $7.16 | $0.46 | 6.87% | 1,594,792 | $6.75 | $7.30 | $6.73 |
| 24 Oct 2024 | $6.70 | $0.01 | 0.15% | 983,189 | $6.57 | $6.72 | $6.51 |
| 23 Oct 2024 | $6.69 | $-0.08 | -1.18% | 1,076,045 | $6.77 | $6.82 | $6.48 |
| 22 Oct 2024 | $6.77 | $0.21 | 3.20% | 1,543,328 | $6.50 | $6.86 | $6.48 |
| 21 Oct 2024 | $6.56 | $-0.22 | -3.24% | 1,017,079 | $6.73 | $6.75 | $6.44 |
| 18 Oct 2024 | $6.78 | $0.27 | 4.15% | 1,752,987 | $6.63 | $6.88 | $6.60 |
| 17 Oct 2024 | $6.51 | $0.01 | 0.15% | 1,946,228 | $6.54 | $6.56 | $6.22 |
| 16 Oct 2024 | $6.50 | $-0.31 | -4.55% | 1,513,383 | $6.81 | $6.92 | $6.49 |
| 15 Oct 2024 | $6.81 | $-0.09 | -1.30% | 3,574,279 | $6.99 | $6.99 | $6.19 |
| 14 Oct 2024 | $6.90 | $-0.07 | -1.00% | 1,400,510 | $7.02 | $7.47 | $6.84 |
| 11 Oct 2024 | $6.97 | $-0.15 | -2.11% | 1,830,698 | $7.01 | $7.14 | $6.76 |
| 10 Oct 2024 | $7.12 | $-0.32 | -4.30% | 3,643,907 | $7.46 | $7.54 | $6.92 |
| 09 Oct 2024 | $7.44 | $-0.23 | -3.00% | 805,133 | $7.70 | $7.72 | $7.38 |
| 08 Oct 2024 | $7.67 | $-0.22 | -2.79% | 1,119,116 | $7.96 | $7.97 | $7.44 |
| 07 Oct 2024 | $7.89 | $0.22 | 2.87% | 1,025,333 | $7.70 | $7.97 | $7.54 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Oct 2024 | Michelle Parker | Buy | 542,710 | $495,000 |
Exercise of options. vwap
|
| 02 Oct 2024 | Michelle Parker | Exercise | 600,000 | $495,000 |
Exercise of options. vwap
|
| 01 Oct 2024 | Thomas Ramdahl | Buy | 200,000 | $165,000 |
Exercise of options. vwap
|
| 01 Oct 2024 | Thomas Ramdahl | Exercise | 200,000 | $165,000 |
Exercise of options. vwap
|
| 01 Oct 2024 | Colin Biggin | Exercise | 1,200,000 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Colin Biggin | Buy | 1,084,321 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Christopher Roberts | Exercise | 200,000 | $165,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Christopher Roberts | Buy | 200,000 | $165,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Alan Taylor | Exercise | 1,200,000 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Alan Taylor | Buy | 1,083,776 | $990,000 |
Exercise of options. VWAP
|
| 17 Sep 2024 | Rosanne Robinson | Buy | 178,079 | $165,000 |
Exercise of options.
|
| 17 Sep 2024 | Rosanne Robinson | Exercise | 200,000 | $165,000 |
Exercise of options.
|
| 07 Aug 2024 | Colin Biggin | Buy | 905,625 | $605,000 |
Exercise of options. vwap
|
| 07 Aug 2024 | Colin Biggin | Exercise | 1,000,000 | $605,000 |
Exercise of options. vwap
|
| 01 Aug 2024 | Colin Biggin | Exercise | 600,000 | $363,000 |
Exercise of options. VWAP
|
| 01 Aug 2024 | Colin Biggin | Buy | 542,835 | $363,000 |
Exercise of options. VWAP
|
| 01 Aug 2024 | Alan Taylor | Buy | 543,002 | $363,000 |
Exercise of options.
|
| 01 Aug 2024 | Alan Taylor | Exercise | 600,000 | $363,000 |
Exercise of options.
|
| 20 May 2024 | Robert Thomas | Buy | 8,333 | $35,706 |
On-market trade.
|
| 20 May 2024 | Robert Thomas | Buy | 7,575 | $32,291 |
On-market trade.
|
| 29 Apr 2024 | Robert Thomas | Issued | 16,667 | $42,500 |
Rights issue.
|
| 29 Apr 2024 | Robert Thomas | Issued | 17,425 | $44,433 |
Rights issue.
|
| 21 Mar 2024 | Thomas Ramdahl | Exercise | 400,000 | $242,000 |
Exercise of options.
|
| 21 Mar 2024 | Thomas Ramdahl | Buy | 400,000 | $242,000 |
Exercise of options.
|
| 12 Dec 2023 | Alan Taylor | Issued | 1,764,981 | $1,596,400 |
Issue of options. Black - Scholes model, VWAP
|
| 12 Dec 2023 | Colin Biggin | Issued | 928,988 | $840,846 |
Issue of options. Black-Scholes, VWAP, As per announcement on 14-12-2023
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Christopher Graham Roberts | Non-Executive Director | Mar 2016 |
Dr Roberts has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. He is member of Risk Committee.
|
| Ms Rosanne Elizabeth Robinson | Lead Independent DirectorNon-Executive Director | Oct 2010 |
Ms Robinson brings experience in the nuclear field and a range of commercial and operational expertise to the Group. She has over 25 years of experience in senior leadership and governance roles in public and private companies and government. She is member of Risk Committee.
|
| Dr Alan John Taylor | Executive ChairmanExecutive Director | Nov 2013 |
Dr Taylor has over 15 years of investment banking experience focused predominantly on the life sciences sector, and has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory.
|
| Dr Colin David Biggin | Chief Executive OfficerManaging Director | Oct 2019 |
Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo for metastatic prostate cancer, which was approved by the US FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
|
| Ms Michelle Parker | Executive Director | Sep 2024 |
Ms Parker has over 20 years of experience spanning nuclear medicine, positron emission tomography and pharmaceuticals in Australia and internationally. Prior to joining Clarity, Ms Parker held the position of Head of International Clinical Research Operations at Novartis Australia
|
| Mr Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
|
| David Green | Chief Financial Officer |
-
|
|
| Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 22,818,280 | 7.23% |
| UBS Nominees Pty Ltd | 19,336,534 | 6.12% |
| Cabbit Pty Ltd Atf Robwill Trust | 17,911,280 | 5.67% |
| J P Morgan Nominees Australia Pty Limited | 16,935,337 | 5.36% |
| T M Ventures Pty Ltd | 16,699,842 | 5.29% |
| HSBC Custody Nominees (Australia) Limited | 14,248,257 | 4.51% |
| A.C.N. 136 437 913 Pty Ltd Atf The Taylor Family A/C | 13,266,660 | 4.20% |
| Argo Investments Limited | 9,802,322 | 3.10% |
| Yarrawah Pty Ltd Atf Peter Henderson P/L S/F A/C | 8,040,000 | 2.55% |
| Vantres Pty Ltd Atf Asten Super Fund A/C | 6,812,340 | 2.16% |
| Boorris Pty Ltd Atf Boorris Trust | 6,065,800 | 1.92% |
| BNP Paribas Noms Pty Ltd | 5,356,049 | 1.70% |
| Pacific Custodians Pty Limited | 5,280,485 | 1.67% |
| Smarter Capital Pty Ltd | 5,004,543 | 1.58% |
| National Nominees Limited | 4,438,511 | 1.41% |
| Kylaco Pty Ltd | 3,896,280 | 1.23% |
| Bnp Paribas Nominees Pty Ltd | 3,713,550 | 1.18% |
| Australian Nuclear Science & Technology Organisation | 3,599,920 | 1.14% |
| Colin Biggin | 3,249,764 | 1.03% |
| Wyargine Holdings Pty Ltd Atf Shellcove Super Fund | 3,210,425 | 1.02% |
